Chorti A, Achilla C, Siasiaridis A, Aristeidis I, Cheva A, Theodosios P
Balkan J Med Genet. 2025; 27(2):33-39.
PMID: 40070855
PMC: 11892936.
DOI: 10.2478/bjmg-2024-0011.
Ampolini E, Jimenez-Sainz J, Long D
Target Oncol. 2025; .
PMID: 40024979
DOI: 10.1007/s11523-025-01136-6.
Zhang T, Cai J, Li C, Xu Y, Xu Y
Hered Cancer Clin Pract. 2025; 23(1):6.
PMID: 39985003
PMC: 11843810.
DOI: 10.1186/s13053-025-00306-x.
Kravchuk D, Lebedeva A, Kuznetsova O, Kavun A, Taraskina A, Belova E
Front Immunol. 2025; 16:1492296.
PMID: 39975556
PMC: 11836019.
DOI: 10.3389/fimmu.2025.1492296.
Zhang Y, Leung A, Kang J, Sun Y, Wu G, Li L
Nat Commun. 2025; 16(1):975.
PMID: 39856048
PMC: 11760531.
DOI: 10.1038/s41467-024-54176-3.
Decoding the functional impact of the cancer genome through protein-protein interactions.
Fu H, Mo X, Ivanov A
Nat Rev Cancer. 2025; 25(3):189-208.
PMID: 39810024
DOI: 10.1038/s41568-024-00784-6.
Leveraging cancer mutation data to inform the pathogenicity classification of germline missense variants.
Haque B, Cheerie D, Pan A, Curtis M, Nalpathamkalam T, Nguyen J
PLoS Genet. 2025; 21(1):e1011540.
PMID: 39761285
PMC: 11737861.
DOI: 10.1371/journal.pgen.1011540.
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).
Zhang L, Deng T, Liufu Z, Liu X, Chen B, Hu Z
Elife. 2024; 13.
PMID: 39688960
PMC: 11651657.
DOI: 10.7554/eLife.99340.
Non-Susceptibility Gene Variants in Head and Neck Paragangliomas.
Snezhkina A, Pavlov V, Krasnov G, Kalinin D, Pudova E, Stolbovskaya O
Int J Mol Sci. 2024; 25(23).
PMID: 39684472
PMC: 11641674.
DOI: 10.3390/ijms252312762.
ETS1 Promotes Aerobic Glycolysis and Growth in Head and Neck Squamous Cell Carcinoma by Targeting RRAS2.
Liu J, Wang Z, Tian X, Xie B, Liu K
Biochem Genet. 2024; .
PMID: 39661306
DOI: 10.1007/s10528-024-10996-y.
A novel necroptosis-related genes signature to predict prognosis and treatment response in bladder cancer.
Yao D, Yu W, Ma X, Tian J
Front Mol Biosci. 2024; 11:1493411.
PMID: 39655212
PMC: 11625674.
DOI: 10.3389/fmolb.2024.1493411.
Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53.
Gong L, Xu D, Ni K, Li J, Mao W, Zhang B
Adv Sci (Weinh). 2024; 12(4):e2402258.
PMID: 39629919
PMC: 11789598.
DOI: 10.1002/advs.202402258.
Analysis of Shared Variants between Cancer Biospecimens.
Foote M, White J, Chatila W, Argiles G, Lu S, Rousseau B
Clin Cancer Res. 2024; 31(2):376-386.
PMID: 39561276
PMC: 11747808.
DOI: 10.1158/1078-0432.CCR-24-1583.
Amplifying mutational profiling of extracellular vesicle mRNA with SCOPE.
Song J, Cho M, Cho H, Song Y, Lee S, Nam H
Nat Biotechnol. 2024; .
PMID: 39375445
DOI: 10.1038/s41587-024-02426-6.
Development and extensive sequencing of a broadly-consented Genome in a Bottle matched tumor-normal pair.
McDaniel J, Patel V, Olson N, He H, He Z, Cole K
bioRxiv. 2024; .
PMID: 39345378
PMC: 11429686.
DOI: 10.1101/2024.09.18.613544.
Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.
Iwasaki T, Shirota H, Sasaki K, Ouchi K, Nakayama Y, Oshikiri H
Cancer Sci. 2024; 115(12):4034-4044.
PMID: 39327066
PMC: 11611756.
DOI: 10.1111/cas.16355.
In Silico Analysis of the Missense Variants of Uncertain Significance of Gene Reported in GnomAD Database.
Caballero-Avendano A, Gutierrez-Angulo M, Ayala-Madrigal M, Moreno-Ortiz J, Gonzalez-Mercado A, Peregrina-Sandoval J
Genes (Basel). 2024; 15(8).
PMID: 39202333
PMC: 11353749.
DOI: 10.3390/genes15080972.
Evolutionary dependency of cancer mutations in gene pairs inferred by nonsynonymous-synonymous mutation ratios.
Han D, Kim S, Lee S, Moon Y, Kang S, Yoo J
Genome Med. 2024; 16(1):103.
PMID: 39160568
PMC: 11331682.
DOI: 10.1186/s13073-024-01376-7.
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Halik A, Tilgner M, Silva P, Estrada N, Altwasser R, Jahn E
J Hematol Oncol. 2024; 17(1):70.
PMID: 39160538
PMC: 11331663.
DOI: 10.1186/s13045-024-01590-1.
Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors.
Kuehn J, Metzger P, Neidert N, Matysiak U, Grassel L, Philipp U
NPJ Precis Oncol. 2024; 8(1):180.
PMID: 39143272
PMC: 11324882.
DOI: 10.1038/s41698-024-00674-y.